Use of 3,1IB-CIS-dihydrotetrabenazine for the treatment of symptoms of Huntington's disease

Details for Australian Patent Application No. 2006268098 (hide)

International Classifications

Event Publications

6 March 2008 PCT application entered the National Phase

PCT publication WO2007/007105 Priority application(s): WO2007/007105

5 June 2008 Amendment Made

The nature of the amendment is: Amend the invention title to read Use of 3,1IB-CIS-dihydrotetrabenazine for the treatment of symptoms of Huntington's disease

1 October 2009 Assignment before Grant

Cambridge Laboratories (Ireland) Limited The application has been assigned to Biovail Laboratories International (Barbados) SRL

17 February 2011 Application Accepted

Published as AU-B-2006268098

16 June 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.